Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Progr...(of 1995. Cadence(TM) Acetavance(TM) a...),Health

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts:

William R. LaRue Anna Gralinska

SVP & Chief Financial Officer Director, Investor Relations

Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.

858-436-1400 858-436-1452

CADENCE PHARMACEUTICALS, INC.

(a development stage company)

CONDENSED STATEMENTS OF OPERATIONS

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Operating expenses:

Research and

development $10,241,943 $10,353,033 $32,463,211 $31,349,828

Marketing 664,143 694,187 2,175,120 1,462,724

General and

administrative 2,754,064 2,555,579 8,323,996 6,819,111

Other 509 - 28,766 -

Total operating

expenses 13,660,659 13,602,799 42,991,093 39,631,663

Loss from

operations (13,660,659) (13,602,799) (42,991,093) (39,631,663)

Other (expense)

income, net (88,336) 616,364 (71,653) 2,150,941

Net loss $(13,748,995) $(12,986,435) $(43,062,746) $(37,480,722)

Basic and diluted

net loss per

share(1) $(0.36) $(0.45) $(1.18) $(1.31)

Shares used to

compute basic and

diluted net loss

per share(1) 38,116,063 28,637,956 36,371,272 28,530,309

(1) As a result of the issuance of 9,240,307 shares of common stock

pursuant to an effective
'/>"/>